Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 533 | 127 | 382 |
| Samples | 280 | 73 | 198 |
| Peptides | 249 | 54 | 191 |
Function
CCNT2 · Cyclin T2
The protein encoded by this gene belongs to the highly conserved cyclin family, whose members are characterized by a dramatic periodicity in protein abundance through the cell cycle. Cyclins function as regulators of CDK kinases. Different cyclins exhibit distinct expression and degradation patterns which contribute to the temporal coordination of each mitotic event. This cyclin and its kinase partner CDK9 were found to be subunits of the transcription elongation factor p-TEFb. The p-TEFb complex containing this cyclin was reported to interact with, and act as a negative regulator of human immunodeficiency virus type 1 (HIV-1) Tat protein. A pseudogene of this gene is found on chromosome 1. Alternate splicing results in multiple transcript variants.[provided by RefSeq, Dec 2010].
Isoforms & Proteins
2 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 232 amino-acid changes on canonical ENST00000264157 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in CCNT2 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in CCNT2 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Chronic Myelogenous Leukemia | 1/25 4% | 0/0 0% |
| Endometrial Carcinoma | 3/42 7% | 19/612 3% |
| T-Lymphoblastic Leukemia | 1/40 2% | 0/0 0% |
| Non-Small Cell Lung Carcinoma | 21/304 7% | 14/1390 1% |
| Germ Cell Tumour | 3/25 12% | 1/169 1% |
| Melanoma | 0/210 0% | 37/1899 2% |
| Burkitts Lymphoma | 3/32 9% | 0/196 0% |
| Cervical Carcinoma | 2/35 6% | 4/422 1% |
| Acute Myeloid Leukemia | 1/90 1% | 0/0 0% |
| Other Solid Cancers | 0/94 0% | 17/1515 1% |
| Colorectal Carcinoma | 7/143 5% | 25/3239 1% |
| Ovarian Carcinoma | 5/109 5% | 5/998 0% |
| Bladder Carcinoma | 0/58 0% | 9/956 1% |
| Mesothelioma | 2/62 3% | 0/165 0% |
| Small Cell Lung Carcinoma | 0/9 0% | 6/752 1% |
| Gastric Carcinoma | 3/74 4% | 11/1809 1% |
| Neuroendocrine Tumour | 4/154 3% | 1/577 0% |
| Squamous Cell Lung Carcinoma | 1/57 2% | 4/810 0% |
| Biliary Tract Carcinoma | 2/54 4% | 3/950 0% |
| Hepatocellular Carcinoma | 0/46 0% | 10/2210 0% |
| Meningioma | 1/3 33% | 0/252 0% |
| Kidney Carcinoma | 4/85 5% | 3/1862 0% |
| Plasma Cell Myeloma | 0/44 0% | 1/305 0% |
| Prostate Carcinoma | 2/13 15% | 4/2105 0% |
| Other Sarcomas | 0/69 0% | 2/699 0% |
| Thyroid Gland Carcinoma | 2/45 4% | 2/1592 0% |
| Esophageal Squamous Cell Carcinoma | 0/51 0% | 6/2550 0% |
| Glioma | 0/52 0% | 5/2127 0% |
| Breast Carcinoma | 2/144 1% | 6/3264 0% |
| Head and Neck Carcinoma | 0/85 0% | 3/1574 0% |
Mutation Distribution
Where CCNT2 is mutated · all tissues, split by cell line vs tissue
How many mutations in CCNT2 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 533 mutations in CCNT2
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|